Treatment for malignant pleural effusion in humans
AssigneeSignpath Pharma, Inc.
InventorsAshleigh Hocking, Peter P. Sordillo, Alexandra L. Farrall, Sonya Klebe
Life of this patent
Estimating the term…
Abstract
The present invention includes method for treating malignant pleural effusion in a human patient comprising: administering to the human patient a therapeutically effective amount of a liposomal curcumin or liposomal curcuminoids intrapleurally, wherein the therapeutically effective amount is sufficient to reduce or treat the malignant pleural effusion.
Claims33
A method for treating malignant pleural effusion in a human patient comprising:
- administering to the human patient a therapeutically effective amount of a liposomal curcumin or liposomal curcuminoids intrapleurally, wherein the therapeutically effective amount is sufficient to reduce or treat the malignant pleural effusion.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method for treating a malignant pleural effusion in a human patient comprising:
- identifying a human patient in need of a treatment for the malignant pleural effusion;
- and
- administering to the human patient a therapeutically effective amount of a liposomal curcumin or liposomal curcuminoids in a pleural space or cavity that is adjacent to at least one of the lung, heart, kidney, or liver, sufficient to reduce or treat the malignant pleural effusion.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.